Opinion/decision on a Paediatric investigation plan (PIP): RoActemra,tocilizumab, decision type: , therapeutic area: , PIP number: P/0354/2022

Human medicines European public assessment report (EPAR): Tolucombi, telmisartan,hydrochlorothiazide, Hypertension, Date of authorisation: 13/03/2013, Revision: 11, Status: Authorised

Saxenda (liraglutide) supply shortage

Tresiba (insulin degludec) supply shortage

Yellow fever vaccine (live) : List of nationally authorised medicinal products - PSUSA/00003135/202212

Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Dengue, Date of authorisation: 12/12/2018, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tecovirimat SIGA, tecovirimat monohydrate, Poxviridae Infections;Cowpox;Monkeypox;Vaccinia;Smallpox, Date of authorisation: 06/01/2022, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Ervebo, Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live), Hemorrhagic Fever, Ebola, Date of authorisation: 11/11/2019, Revision: 8, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Iscalimab, decision type: , therapeutic area: , PIP number: P/0222/2021

Human medicines European public assessment report (EPAR): Aubagio, teriflunomide, Multiple Sclerosis, Date of authorisation: 26/08/2013, Revision: 26, Status: Authorised